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Abstract
Background: Hepatitis C virus (HCV) is a plus-strand RNA virus that replicates by amplification of genomic RNA from minus
strands leading to accumulation of almost one thousand copies per cell under in vitro cell culture conditions. In contrast,
HCV RNA copy numbers in livers of infected patients appear to be much lower, estimated at a few copies per cell.
Methodology/Principal Findings: To gain insights into mechanisms that control HCV replication in vivo, we analyzed HCV
RNA levels as well as expression of interferon beta (IFNb) and several interferon stimulated genes (ISGs) from whole liver
sections and micro-dissected subpopulations of hepatocytes in biopsy samples from 21 HCV-infected patients. The results
showed that intrahepatic HCV RNA levels range form less than one copy per hepatocyte to a maximum of about eight. A
correlation existed between viral RNA levels and IFNb expression, but not between viral RNA and ISG levels. Also, IFNb
expression did not correlate with ISGs levels. Replication of HCV RNA occurred in focal areas in the liver in the presence of a
general induction of ISGs.
Conclusion/Significance: The low average levels of HCV RNA in biopsy samples can be explained by focal distribution of
infected hepatocytes. HCV replication directly induces IFNb, which then activates ISGs. The apparent lack of a correlation
between levels of IFNb and ISG expression indicates that control of the innate immune response during HCV infections
depends on multiple factors.
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Introduction
Hepatitis C virus (HCV) is a major human pathogen that
chronically infects an estimated 180 million people worldwide [1].
HCV replicates in hepatocytes, which then become the target of
an inflammatory response that leads to progressive fibrosis of the
liver, culminating in cirrhosis and often hepatocellular carcinoma,
both of which cause significant morbidity and mortality. In the
United States, HCV infection is the predominant cause for liver
failure and orthotopic liver transplantations (OLT). However,
near-universal graft re-infection results in accelerated fibrosis and
cirrhosis of the allograft [2]. While a cure from HCV infections
can be achieved in approximately 50% of infected patients with
interferon-alpha (IFNa)-based therapy, the mechanism by which
therapy can cure patients remains unclear.
HCV is a plus-strand RNA virus belonging to the Flaviviridae
family of viruses, which include several other human pathogens
such as West Nile (WNV) and Dengue viruses [3]. As with other
plus-strand RNA viruses, HCV infections in tissue culture cells
result in rapid amplification of the viral genome leading to the
accumulation of several hundred to a few thousand genomes per
cell [4,5]. HCV replication in tissue culture cells is very sensitive to
treatment with IFNa/b and IFNc [6,7,8]. Similarly, HCV
replication is also inhibited in vivo by IFNa, although sensitivity
to the cytokine varies among patients for reasons that are not well
understood [9,10].
The discovery that HCV infections in chimpanzees and humans
induce expression of genes that are normally activated by IFNs,
could explain why HCV RNA and protein levels are very low in
infected livers [11,12,13,14]. Consistent with this view, a study
with experimentally infected chimpanzees revealed that on
average liver cells carry less than 10 copies of HCV plus strand
RNA [15]. Similarly, PCR-based RNA analyses of RNA isolated
from biopsy samples from infected human patients suggested the
presence of only very low average copy numbers [16]. By contrast,
several studies using less sensitive in situ hybridization methods for
the detection of viral plus- and minus-strand RNA nonetheless
provided evidence for much more robust HCV RNA replication
levels [17,18]. In addition to these conflicting results regarding the
overall levels of HCV RNA replication in infected livers, the
distribution of infected hepatocytes, e.g. whether HCV replicates
in a subpopulation of cells as efficiently as observed in tissue
culture cells, or whether it replicates in a large fraction of
hepatocytes with a few copies of RNA per cell, remains unknown.
The first scenario might suggest a model in which ISGs are
globally activated but locally repressed (i.e. by the virus) to allow
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would invoke a model in which amplified RNA is rapidly degraded
due to the highly up-regulated ISGs. The second model would
predict a correlation between viral RNA load in the liver and
activation of ISGs. Clarification of whether focal inactivation of
ISGs can explain persistence of HCV infections could have an
impact on the design of future antiviral therapies.
To determine the distribution of HCV and ISG expressing cells,
we have performed gene expression analyses on frozen liver
sections from HCV infected patients. We found that only a
subpopulation of hepatocytes expresses detectable levels of HCV
RNA, while cells expressing ISGs are more uniformly distributed
in the liver. Consistent with previous PCR-based studies, we
estimated that the average copy number per hepatocyte ranges
from less than one to about 10 copies of viral RNA per hepatocyte.
Materials and Methods
Liver tissue
Liver tissues were obtained from patients undergoing liver
needle biopsies for diagnostic purposes. All patients signed consent
forms to acknowledge participation in this study approved by the
institutional review board of the Fox Chase Cancer Center,
Philadelphia, the University of Pennsylvania, Philadelphia and the
University of Florida, Gainesville. Fractions of the core of the
needle biopsies were snap frozen in liquid nitrogen immediately
following the procedures, embedded in OTC and stored at
280uC. Frozen sections were prepared with a cryostat (CM1850,
LEICA) set at 7 mm. Sections were mounted onto non-charged
Premium Microscope slides (12-544-2, Fisher), placed immediately
into a slide box on dry cry ice and stored at 280uC.
Laser capture microdissection (LCM) and RNA isolation
Tissue sections were stained with hematoxylin/eosin using the
HistoGene kit (Arcturus). Cells were captured with a laser capture
microdissection microscope (Veritas, Arcturus) using HS caps
(Arcturus). The power and pulse settings were adjusted to achieve
a spot size of 22–24 mm. The number of hits was set to position 5.
Isolation of total RNA from the captured cells was performed with
the PicoPure RNA Isolation Kit (0204, Arcturus). For the isolation
of total RNA from whole tissue sections and from HCV expressing
GS4.1 cells the same protocol was followed.
cDNA Synthesis and DNA amplification
The High Capacity cDNA Archive kit (4322171, ABI) was used
for cDNA synthesis. cDNAs were pre-amplified with a PreAmp kit
from ABI (4366381). The pooled TaqMan probe/primer mix
consisted of a mixture of the TaqMan primers specific for the
selected genes (Table S1). The reactions were performed in a
thermocycler for 9 (whole sections) or 14 (LCM samples and
GS4.1 RNA) cycles. The samples were diluted 1:5 with 200 ul of
TE and stored at –80uC. Note that the reactions did not contain
the primer set for 18S RNA. The real-time PCR reactions were
carried out in a total volume of 25 ml in an ABI7900 SDS
instrument.
Calculation of HCV copy numbers
HCV copy numbers shown in Figure 1B were computed as
follows: First, the Ct values obtained for HCV RNA levels were
normalized with albumin with the following formula: 2
‘-(Cthcv-
Ctalb). Then, the calculated values from tissue culture cells (GS4.1)
were divided by the values from liver tissues and multiplied by
1000, the estimated copy number of HCV RNA in GS4.1 cells,
which yielded the number of HCV RNA copies/liver cell. This
number was multiplied by 1.43 (1/0.7) to adjust for the 70%
fraction of hepatocytes in liver tissue.
Western blot
To prepare protein extracts, OTC was dissolved in PBS and the
tissue sample transferred to lysis buffer (10 mM Tris (pH 8),
150 mM sodium chloride, 0.5% deoxycholic acid, 0.1% sodium
dodecyl sulfate, 1% triton-X100) and protease inhibitor cocktail
(Roche). Proteins (20 mg) were separated by 10% SDS-PAGE and
transferred to Immobilon-P (Millipore). Membranes were probed
with the indicated antibodies.
Statistical analysis
Regression analysis was used to determine the significance of
trend lines. To obtain cut points for positive samples in P2 and P4,
the following formula was used: limit over which HCV is.null
mean+1.96 std. The mean and standard deviations of the data for
control (uninfected) patient P1 (null) were 0.793 and 1.088,
respectively. The calculated value for the limit was 2.925. The list
of entries for which HCV.2.925 included P2-13, P4-12, P4-14P,
P4-23, P4-32, P4-34P, P4-41, P4-62 and P4-71P.
Results
Patient cohort and viral RNA titers
The cohortforthis study consisted ofpatients chronicallyinfected
with HCV belonging to genotypes 1 (11/21), 2 (1/21), 3 (2/21) and
6 (5/21)(Table1).Onetissuesample(P1)was obtainedfrom acolon
cancer patient that was not infected with HCV, HBV or HIV and
seven were derived from transplanted livers. Biopsies from patients
2–7 were obtained following OLT and during treatment with
immunosuppressants. Patients 9 and 13 received IFN therapy prior
to the liver biopsies. None of the patients received IFN therapy at
the time of liver biopsy. Viral load (VL) in serum differed
significantly among patients, ranging from about 1.2610
‘5t o
2.4610
‘7 genomes/ml. To investigate whether a correlation
existed between viral load in blood and viral RNA in liver, we
determined HCV RNA levels in tissue sections prepared from liver
biopsies. To account for differences in the number of cells on
histological sections used for RNA extraction, we normalized the
values for HCV RNA levels with those for albumin. The results
showed that the correlation between serum RNA and liver RNA
levels was statistically significant (P=3.63E-03) (Figure 1A). These
results were consistent with those from a study by Vona et al. with a
cohort of about 20 HCV infected patients [16]. Moreover,
consistent with that study, we did not observe a correlation between
HCV RNA levels and fibrosis or inflammation.
To obtain an estimate for the copy number of HCV RNA in
infected liver tissue, we compared HCV RNAlevels in tissue culture
cells expressing HCV subgenomic replicon (the Huh7-derived
GS4.1 cell line [5]) with those in infected livers using values for
HCV RNA and albumin obtained with the same RNA purification
and qRT-PCR methods. We based our calculations on the
assumption that albumin levels in the GS4.1 cells are comparable
with those in hepatocytes in vivo and on information about the copy
number of HCV RNA in those cells, which was estimated to be
about 1000 per cell based on northern blot analysis [5]. Based on
our calculations (see legend to Figure 1B), the copy number of HCV
RNA in the livers of our patient cohort ranged from less than one
copy per hepatocyte to a maximum of 7.5 copies in patient 6
(Figure 1B). Since the ratio between plus- and minus-strand RNA in
HCV and other plus-strand RNA viruses is generally believed to be
in the range of 10:1 [4], our results indicated either that only a
fraction of hepatocytes was infected or that the ratio of plus- to
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culture cells or that a combination of the two possibilities existed.
The HCV protease NS3 cleaves the cellular protein IPS1,
which leads to an inhibition of the signal transduction pathway for
expression of IFNb in response to viral infections [19,20].
Therefore, cleaved IPS1 can be used as a reporter for HCV
replication in infected cells. We have analyzed IPS1 by western
blot analysis of protein extracts from normal and HCV infected
tissue culture cells and from eight patient samples. The results
showed that in infected tissue culture cells IPS1 is completely
cleaved (Figure 1C). In contrast, in most patient samples IPS1
migrated as a full-length protein (Figure 1C, results not shown).
The highest fraction of cleaved IPS1 was observed in extracts from
patient P19, which correlated with the relatively high HCV RNA
levels identified in the same liver (4 copies/hepatocyte, Figure 1B).
Considering that hepatocytes represent 70–80% of the total liver
cell mass [21], the estimated 40% cleavage of IPS1 observed in this
patient could indicate that a relatively large fraction of hepatocytes
were infected, unless IPS1 cleavage was caused by a cellular
enzyme in uninfected cells in response to inflammation (see
Discussion). It should be noted that the levels of HCV core were
below the detection limit of our western blot analysis (even in
patient P19) and hence, at least 10-fold lower than observed with
HCV-infected tissue culture cells (Figure 1C). Thus, the results
from protein analyses were consistent with the qRT-PCR results
and suggested that in the majority of cases examined only a
fraction of hepatocytes in vivo expressed HCV proteins.
Activation of an IFN response in HCV-infected patients
DNA microarray studies with liver tissue from acutely HCV-
infected chimpanzees and chronically infected human patients
revealed that HCV replication induces interferon stimulated genes
Figure1. Correlation between HCV RNA in serum andliver. (A) Values for viral RNA in serum (x-axis) were plotted against HCV RNA levels (y-axis)
infrozensections fromneedlebiopsiesdeterminedbyquantitativereal-timePCR(qRT-PCR).Thevalueswerenormalizedwithalbumin andexpressedon
a scale from 0 to 100. (B) The plot shows the estimated copy number of HCV RNA per hepatocyte for each of the 22 patients listed in Table 1. C) The
figureshowsawesternblotanalysiswithproteinextractsfromnormal, uninfectedHuh7cells(U), HCVJC1infectedHuh7 cells(JC1)andfromlivertissues
of patients 12, 17,18 and 19 (see Table 1). The blot was incubated with antibodies specific for the indicated proteins. Core, HCV core protein.
doi:10.1371/journal.pone.0006661.g001
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IFNb, which, in turn activates the IFN signal transduction
pathway leading to the expression of ISGs [22,23]. Whether the
source of interferon responsible for ISG induction primarily is
autocrine IFNb from infected hepatocytes, paracrine IFNb from
vascular-associated non-parenchymal cells (e.g. liver sinusoidal
endothelial cells, stellate cells, Kupffer cells, and portal myofibro-
blasts), or paracrine IFNc produced by infiltrating lymphocytes
remains unknown. To investigate whether a relationship existed
between HCV RNA levels, IFNb production and ISG expression,
we determined RNA expression levels of IFNb, IFIT1 and Mx1.
All (21) HCV-infected patients examined in this study exhibited
elevated IFNb mRNA levels compared to the uninfected patient
P1 (Figure 2A). The range of induction varied from about 8 in
patient P15 to over 1000-fold in patient P19 compared with the
uninfected patient P1. Viral load in the liver and expression of
IFNb expression correlated (p=3.04E-3), suggesting that virus
replication proportionally activated expression of the cytokine (see
Discussion). Notably, the correlation between HCV RNA and
IFNb would be even stronger were the outlier P18 omitted from
the regression analysis (p=1.22E-4). In contrast, HCV RNA levels
did not correlate with those of the ISG, Mx1 (Figure 2B). With one
exception (P16), Mx1 levels were elevated in all patients compared
to P1, although in 3 patients the increase was less than 2-fold
(Figure 2B). Similar results were obtained when IFIT1 levels were
used in lieu of Mx1, because the expression levels of the two ISGs
correlated very well in individual patients (p,10E-4, Figure 2D).
A similar correlation was observed between Mx1 and IFI27, a
third ISG analyzed in this study (Figure S1). By contrast, levels of
IFNb and Mx1 induction did not correlate, suggesting that
activation of ISGs is not directly controlled by IFNb in HCV-
infected livers (Figure 2C, see Discussion).
Distribution of HCV and ISG RNA in liver
To determine the distribution of HCV and ISG RNA in liver
sections, we used laser capture microdissection (LCM) to isolate
small groups of about 100–200 hepatocytes and isolated RNA for
real-time qRT-PCR analysis. To perform these investigations we
selected frozen sections from patients P1 (control, uninfected), P2
and P4. Tissue sections from patients P2 and P4 did not exhibit
fibrosis and were relatively large and, hence suitable for isolation
of cells by LCM. Both patients underwent OLT approximately 4
months prior to the biopsy (Table 1). Because HCV RNA titers
approach or surpass pre-transplantation RNA levels within a few
days following surgery, intrahepatic RNA levels were at steady-
state long before the biopsies were obtained [24,25]. The
estimated load of HCV in biopsies of infected liver grafts was
0.01 (P2) and 1.3 (P4) RNA copies per hepatocyte, respectively
(Figure 1B). To investigate the distribution of HCV-infected cells
and cells expressing Mx1, we performed real-time qRT-PCR
analysis on the same RNA samples. The results showed that Mx1
expression levels were elevated to a similar degree in all samples
obtained from HCV-infected patients P2 and P4 compared with
the samples from HCV naive patient P1 (Figure 3A). Consistent
with the results obtained from the analysis of whole tissue sections
(Figure 2D), Mx1 RNA levels were on average higher in cells
collected from patient P4 than from patient P2. In contrast to the
observations made with Mx1, HCV RNA levels differed
significantly among the samples analyzed (Figure 3B). For patient
P2, only 1 of 11 (9%) samples analyzed exhibited significantly
elevated HCV RNA levels, and for P4, 8 of 19 (42%) samples were
positive (see Materials and Methods). Hence, the results clearly
demonstrated that the presence of HCV RNA in infected liver
tissue is focal, not uniform, as observed with ISGs Mx1 or IFIT1
(see Discussion).
Discussion
The purpose of this study was to investigate the distribution of
infected hepatocytes in chronic HCV infections and to determine
whether a correlation exists between viral load in the liver and
induction of IFNb and ISGs. The results revealed that HCV
infected hepatocytes are focally distributed in infected livers,
explaining the surprisingly low average levels of HCV RNA in
biopsy samples. Moreover, they provided evidence for a
correlation between viral load and IFNb expression, suggesting
that viral replication could directly induce an antiviral state.
However, the correlation between levels of IFNb and ISG
expression were insignificant, suggesting that control of the innate
immune response during HCV infections depends on multiple
factors.
Our study showed low average levels of HCV in the liver. Over
50% of tissue samples analyzed exhibited less that one copy of viral
RNA per hepatocyte (Figure 1B). Patient P6 with the highest viral
load among patients examined in this study (7–8 RNA copies/
hepatocyte), still exhibited about 100-fold lower RNA levels than
tissue culture cells expressing HCV replicons or infectious virus
[5]. Consistent with these results, we observed, with one exception
(P19, discussed below) only minor or no cleavage of IPS1, a known
Table 1. Patient cohort.
Patient Race GT VL (x10
6) ALT FIBR INFL RESPONSE
P1 NA 0 ND 0 0 NA
P2
* C 3 ND ND 0 2 NA
P3
* C 1 ND ND 0 1 NA
P4
* C 1 ND 50 0 2 SVR
P5
* C 1 ND ND 0 0-1 NA
P6
* C 1a 11.6 226 1 1 NA
P7
* B 1 2.8 573 0-1 1 NA
P8 B 1a 0.85 84 0-1 1 NA
P9 C 1a 14.3 36UNL 3-4 2-3 RE
P10 B 1a 0.32 26UNL 0 2-3 SVR
P11 A 1b 3.7 26UNL 0 2 SVR
P12 A 1b 9.0 1-26UNL 0 1-2 SVR
P13 C 3a 0.67 3-46UNL 3-4 3-4 RR/SVR
P14 A 6a 0.12 2-36UNL 4 4 RR/SVR
P15 C 2 0.67 2-36UNL 3 2 RR/SVR
P16 A 6,HB 14.0 Normal 0 0-1 SVR
P17 A 1b 3.7 1.56UNL 1 2 SVR
P18 C 1b 0.256 1.56UNL 2 2 NA
P19 A 6 23.6 Normal 1 1-2 RR/SVR
P20 A 6 6.1 26UNL 1 1-2 SVR
P21 C 1 11.5 26UNL 2 2 ETR/RE
P22 A 6 18.0 Normal 1 1-2 RR/ETR/RE
*Patient underwent OLT prior to liver biopsy. HB, HBV co-infection; unl, upper
normal limit; RE, relapse; RR, rapid response (HCV RNA (-) at 4–5 weeks of
therapy; SVR, sustained viral response (HCV RNA (-) for .24 weeks post
therapy); ETR, HCV RNA (-) at end of therapy; UNL, upper normal level, ND, not
done; NA, not applicable; GT, HCV genotype, VL, viral load; ALT, (serum) alanine
aminotransferase; FIBR, fibrosis (scoring range: 0–4 [31]), INFL, portal
inflammation (scoring range 0–4 [31]).
doi:10.1371/journal.pone.0006661.t001
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core or NS5A proteins could not be detected in any of the patient
samples analyzed so far, again reflecting the low average level of
HCV replication in infected livers compared with replication in
tissue culture cells (Figure 1C, results not shown). In tissue culture
and livers of infected chimpanzees, the ratio between HCV plus to
minus strands equals about 10 [4,26]. Assuming a similar ratio in
our patient cohort, near complete infection of hepatocytes could
only have occurred with patient P6, provided that a single
replication complex with one copy of minus strand DNA is
sufficient to sustain an infection. In the majority of our patient
cohort, 10% or fewer hepatocytes were infected. In this regard,
our results were consistent with previous reports relying on qRT-
PCR analysis (i.e. refs. [15,16,27]).
The hypothesis that focal replication could explain the low
average levels of HCV RNA in infected livers was supported by
our analysis of captured hepatocyte pools from frozen sections.
Consistent with the very low RNA copy calculated for patient P2
(Figure 1B), less than 10% of the samples analyzed exhibited HCV
levels that were significantly above background levels (Figure 3B).
In the case of patient P4, who had higher average RNA levels
compared with P2, 16% of the samples were strongly positive for
HCV and another 26% were significantly elevated above
background levels. In contrast to HCV, ISG levels were uniformly
elevated in all samples from both patients. Therefore, we
concluded that HCV is distributed in a piecemeal fashion in
infected livers with infected and uninfected cells present at the
same time (Figure 3B). We compared results from our qRT-PCR
analysis with immunohistochemical analyses using paraformalde-
hyde fixed sections from patients P4, P6, and P9 incubated with
NS5A-specific antibodies (Figure S2). The results were consistent
with a model predicting focal distribution of HCV. However,
similar experiments based on immunofluorescence were inconclu-
sive due to high background caused by autofluorescence of liver
tissue (results not shown).
How can we integrate these observations into a plausible model
for natural HCV infections? An important issue concerns
susceptibility of the hepatocyte population to HCV infection.
Can all hepatocytes be infected or are some resistant? The latter
possibility could be a consequence of selection of resistant
hepatocytes during the course of chronic infections, which is
characterized by continuous cell killing and regeneration of
hepatocytes. We do not favor this possibility, because our analyses
with small cell populations were performed with tissue samples
from two patients (P2, P4) who underwent liver transplantation
about 4 months before the biopsies were taken. Such a short time
period is not sufficient for replacement of a large fraction of
hepatocytes with a virus resistant population. A more plausible
explanation would be that activation of an antiviral state either
protects uninfected hepatocytes from de novo infection or induces
clearance of infected hepatocytes. The latter possibility predicts
that HCV replication in hepatocytes is transient in vivo. However,
our results cannot definitively distinguish between the two models.
They demonstrated that ISG expression is uniform in the liver
Figure 2. Correlation between HCV RNA and activation of IFNb and ISGs. The Ct values for HCV, IFNb, Mx1 and IFIT1 obtained from real-time
qRT-PCR were plotted in different combinations as indicated. Ctn represents Ct values that were normalized with the Ct for albumin to account for
the difference in cell number on each frozen section used for RNA isolation. Note, that Ct values and concentration of RNA are inversely related and
that a difference of 1 in the Ct value corresponds to a two-fold difference in concentration.
doi:10.1371/journal.pone.0006661.g002
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reports demonstrating that ISG induction accompanies HCV
infections independently of genotype, inflammation or fibrosis
levels [11,12,13,15,27].
A major unresolved question concerns the mechanism respon-
sible for ISG induction. Does infection of hepatocytes induce IFNb
or do resident endothelial cells, Kupffer cells, or infiltrating
lymphocytes release IFNa/b or IFNc [28] in response to HCV
replication? While our experiments provided evidence for a
positive correlation between intrahepatic HCV RNA and IFNb
expression levels (Figure 2A), and hence, indicated that infected
hepatocytes are the primary inducer of IFNb, they did not identify
the cells producing the cytokine. The observation that the viral
protease could cleave and inactivate IPS1, an upstream mediator
of IFNb production would indicate that non-parenchymal cells are
the primary source of IFN production. On the other hand, it is
equally possible that infected hepatocytes produce IFNb because
they might sense HCV immediately after infection, prior to
accumulation of sufficient amounts of protease necessary to cleave
and inactivate IPS1. Most likely, both, hepatocytes and infiltrating
immune cells contribute to the expression of IFNb observed in
HCV infected patients. However, identification of the principal
source of IFNb production remains an important unresolved
question.
The lack of a correlation between IFNb and ISG production
was unexpected. It is conceivable that the expression levels of
IFNb were very low and that the primary source of IFN in infected
livers was IFN expressed from resident Kupffer cells or infiltrating
lymphocytes. Also, such a mechanism would not require a strict
correlation between viral replication and ISG induction, because
recruitment of lymphocytes depends on many factors that can vary
among patients including haplotype, diversity of the T and B cell
repertoire and the production of chemokines and cytokines.
As noted above, we observed significant cleavage of IPS1 with
protein extract from patient P19 (Figure 1C). Considering that
normal liver consists of about 80% hepatocytes [21] and assuming
that infiltrating lymphocytes account for at least 10% of total liver
mass, the observed 50% cleavage of IPS1 would indicate that
more than 70% of the hepatocytes were productively infected in
this patient. However, this interpretation is inconsistent with the
very low levels of core protein in the same sample, which could not
be detected by western blot analysis (Figure 1C). Also, the results of
another study demonstrating complete cleavage of IPS1 in some
patient samples, are not consistent with a model explaining that
IPS1 cleavage is limited to infected hepatocytes [29]. Instead,
those results could be explained if IPS1 cleavage were mediated, at
least in part, by a cellular protease that is activated by the
inflammatory response independently of HCV infection. Hence, it
is possible that cellular enzymes induced during inflammation
account at least for some of the cleavage of IPS1 observed during
HCV infections. Notably, it has just been reported that IPS1 is a
substrate for certain caspases in cells induced to enter an apoptotic
program [30].
In summary, this study, together with previous reports,
demonstrated that HCV replication occurs in the face of an
innate immune response that inhibits accumulation of viral RNA.
Activation of ISGs could be important for maintaining chronic
infections by preventing killing of infected hepatocytes either
directly by the virus, or indirectly by cytotoxic T cells. The
observation that HCV replicates in subpopulations of hepatocytes
Figure 3. Focal accumulation of HCV RNA. A) The bar graph shows the levels of Mx1 and IFIT1 expression in groups of about 100 cells that were
isolated by LCM from frozen section of patients P1, P2 and P4. Ct values obtained for the indicated genes were normalized with Ct for18S RNA.
Expression levels are expressed on a scale from 0 to 100. B) Same as A except that the values for HCV RNA were displayed. The samples were sorted in
order of the patients (P1, P2, P4) as indicated in the figure.
doi:10.1371/journal.pone.0006661.g003
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possibility that HCV replication is transient in hepatocytes. Thus,
chronic infections might depend on continuous cycles of infection
and clearance of hepatocytes. Such a model would predict that
inhibitors of de novo HCV infections would be effective for antiviral
therapy. Thus, mechanisms controlling virus attachment, uptake,
uncoating, and delivery of the viral genome to ribosomes might be
excellent targets for novel antiviral drugs. Once identified, they
could be combined with available protease and polymerase
inhibitors and yield highly active antiviral therapies that might
cure chronic HCV infections.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0006661.s001 (0.04 MB
DOC)
Figure S1 Correlation between IFI27 and Mx1 expression. For
an explanation of the figure see the legend to Figure 2.
Found at: doi:10.1371/journal.pone.0006661.s002 (2.28 MB TIF)
Figure S2 NS5A expression in liver sections. Frozen sections
were fixed with paraformaldehyde and incubated with NS5A
monoclonal antibodies. Biotinylated antibodies against mouse IgG
(DAKO, Inc.) were used as secondary antibodies. Tissue sections
were incubated with peroxidase-labeled streptavidin and devel-
oped with 0.5 mg/ml of diaminobenzidine (DAB) in 0.03%
hydrogen peroxide PBS. Sections were counterstained with
hematoxylin, dehydrated in ethanol, and mounted with Permount.
Found at: doi:10.1371/journal.pone.0006661.s003 (2.28 MB TIF)
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